SHIONOGI INTEGRATED SYMPOSIUM AT ECCMID 2022
|
Treating Gram-negative infections caused by pathogens with limited treatment options: Unanswered questions and emerging evidence
|
Monday 25th April 2022, Hall Q, 13:30–15:30
|
|
|
|
Chair: Prof. Dominic Wichmann, University Medical Center Hamburg-Eppendorf, Germany
|
|
|
ESCMID-appointed Chair: Prof. Antti J. Hakanen, Turku University Hospital, Clinical Microbiology, Finland
|
|
|
|
Dr Luke Moore, Chelsea & Westminster NHS Foundation Trust, UK
|
|
Dr Cruz Soriano, Hospital Ramón y Cajal, Spain
|
|
Prof. Maddalena Giannella, IRCCS Policlinico di Sant’Orsola, Italy
|
|
|
|
Welcome & introduction Prof. Dominic Wichmann Prof. Antti J. Hakanen
|
|
|
|
Current therapeutic options for carbapenem-resistant Enterobacterales Dr Luke Moore
|
|
|
|
Addressing the unmet need for Pseudomonas aeruginosa with limited treatment options Dr Cruz Soriano
|
|
|
|
Emerging real-world evidence for the treatment of carbapenem-resistant Acinetobacter baumannii Prof. Maddalena Giannella
|
|
|
|
Panel discussion and audience Q&A
|
|
|
|
Reflection points & meeting close Prof. Dominic Wichmann Prof. Antti J. Hakanen
|
|
|
The Shionogi booth can be found next to the posterboards
|
|
|
|
Fetcroja® is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.1
|
|
|
|
This event has been organised and funded by Shionogi B.V.
PP-PT-FDC-0012 Date of preparation: April 2022
|
|
|
|
|